Albireo Pharma (ALBO)

Company Profile

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Company profile

Ticker

ALBO

Exchange

NASDAQ

Website

www.albireopharma.com

CEO

Ronald Cooper

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Biodel Inc

SEC CIK

0001322505

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Albireo AB, a limited liability company • Elobix AB, a limited liability company • Albireo Pharma Limited, a limited liability company • Albireo Pharma Security Corporation ...

ALBO stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$43.50

Low target

$42.00

High target

$48.00

Latest filings (excl ownership)

View all

SC 14D9/A

Tender offer solicitation (amended)

30 Jan 23

SC 14D9

Tender offer solicitation

23 Jan 23

SC TO-T

Third party tender offer statement

23 Jan 23

SC14D9C

Written communication relating to third party tender offer

19 Jan 23

SC TO-C

Information about tender offer

10 Jan 23

SC TO-C

Information about tender offer

9 Jan 23

SC14D9C

Written communication relating to third party tender offer

9 Jan 23

8-K

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

9 Jan 23

8-K

Departure of Directors or Certain Officers

8 Nov 22

Transcripts

View all

ALBO

Earnings call transcript

2022 Q3

9 Nov 22

ALBO

Earnings call transcript

2022 Q2

16 Aug 22

ALBO

Earnings call transcript

2022 Q1

17 May 22

ALBO

Earnings call transcript

2021 Q4

1 Mar 22

ALBO

Earnings call transcript

2021 Q3

4 Nov 21

ALBO

Earnings call transcript

2021 Q2

7 Aug 21

ALBO

Earnings call transcript

2021 Q1

8 May 21

ALBO

Earnings call transcript

2020 Q4

26 Feb 21

ALBO

Earnings call transcript

2020 Q2

8 Aug 20

ALBO

Earnings call transcript

2020 Q1

10 May 20

Latest ownership filings

View all

FEDERATED HERMES, INC.

Ronald Harold Wilfred Cooper

Financial summary

Financial statements Chart ALBO financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	272.48 mm	272.48 mm	272.48 mm	272.48 mm	272.48 mm	272.48 mm
Cash burn (monthly)	(no burn)	(no burn)	12.60 mm	10.78 mm	9.88 mm	9.61 mm
Cash used (since last report)	n/a	n/a	52.99 mm	45.32 mm	41.54 mm	40.42 mm
Cash remaining	n/a	n/a	219.49 mm	227.16 mm	230.94 mm	232.06 mm
Runway (months of cash)	n/a	n/a	17.4	21.1	23.4	24.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ALBO institutional ownership history Ownership history

94.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	106	102	+3.9%
Opened positions	21	17	+23.5%
Closed positions	17	25	-32.0%
Increased positions	43	36	+19.4%
Reduced positions	26	34	-23.5%

13F shares	Current	Prev Q	Change
Total value	375.02 mm	347.16 mm	+8.0%
Total shares	19.49 mm	17.48 mm	+11.5%
Total puts	76.90 k	28.10 k	+173.7%
Total calls	111.60 k	100.90 k	+10.6%
Total put/call ratio	0.7	0.3	+147.4%

Largest owners	Shares	Value	Change
Perceptive Advisors	2.36 mm	$45.69 mm	0.0%
FHI Federated Hermes	2.26 mm	$43.72 mm	+0.1%
BLK Blackrock	1.22 mm	$23.53 mm	+0.2%
Chicago Capital	1.12 mm	$21.68 mm	-17.1%
Deep Track Capital	1.11 mm	$21.50 mm	NEW
Tang Capital Partners	1.10 mm	$20.10 mm	NEW
Tang Capital Management	1.10 mm	$21.29 mm	+57.1%
BEN Franklin Resources	925.30 k	$17.91 mm	+6.0%
Vanguard	917.48 k	$17.76 mm	-7.7%
ArrowMark Colorado	791.25 k	$15.32 mm	+30.4%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-1.42 mm	EXIT
Deep Track Capital	1.11 mm	+1.11 mm	NEW
Tang Capital Partners	1.10 mm	+1.10 mm	NEW
Millennium Management	511.48 k	+479.02 k	+1476.0%
Nicholas Investment Partners	0.00	-430.88 k	EXIT
Tang Capital Management	1.10 mm	+399.52 k	+57.1%
Sphera Funds Management	359.00 k	+359.00 k	NEW
GW&K Investment Management	643.79 k	+315.11 k	+95.9%
Chicago Capital	1.12 mm	-231.46 k	-17.1%
J. Goldman & Co	0.00	-231.28 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALBO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Jan 23	Martha J. Carter	Common Stock	Sell	Dispose S	No	Yes	43.8	120	5.26 k	14,506
23 Jan 23	Duncan Jason	Common Stock	Sell	Dispose S	No	Yes	43.8	228	9.99 k	14,146
23 Jan 23	Harford Simon N.R.	Common Stock	Sell	Dispose S	No	Yes	43.8	102	4.47 k	32,689
23 Jan 23	Cooper Ronald Harold Wilfred	Common Stock	Sell	Dispose S	No	Yes	43.8	1,057	46.30 k	57,444
23 Jan 23	Jan Mattsson	Common Stock	Sell	Dispose S	No	Yes	43.8	197	8.63 k	54,474